Zasocitinib, a tyrosine kinase 2 (TYK2) inhibitor, at oral doses of ≥ 5 mg led to greater skin clearance than placebo over a period of 12 weeks, in a phase 2b study. Researchers performed a ...
Recombinant antibodies were purified from the cell culture medium, and their potential applications were evaluated using hemagglutination inhibition (HI), western blotting (WB), confocal microscopy, ...
The efficacy of individual treatment approaches with contrasting cholinergic and glutamatergic mechanisms of action prompted investigation of the effects of targeting both systems for the ...